Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 11/20 | 0.41 |
| ▸ | IDH2 | P48735 | 3/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.38 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | GPR39 | O43194 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15102463 | 0.88 | IDH1 (0.51) | SMN1; SMN2ALDH1A1IDH1IDH2GBA1 | |
| SCHEMBL16392219 | 0.85 | IDH2 (0.42) | IDH1IDH2TNNI3K | |
| SCHEMBL16391999 | 0.83 | TNNI3K (0.45) | IDH1IDH2TNNI3KEGFR | |
| SCHEMBL16391734 | 0.80 | MAPT (0.43) | SMN1; SMN2ALDH1A1IDH1 | |
| SCHEMBL16388550 | 0.79 | IDH1 (0.51) | SMN1; SMN2ALDH1A1IDH1IDH2GBA1 | |
| SCHEMBL16391870 | 0.76 | ABCG2 (0.52) | IDH1IDH2 | |
| SCHEMBL16392088 | 0.76 | IDH1 (0.55) | IDH1IDH2 | |
| SCHEMBL16391701 | 0.75 | IDH1 (0.43) | IDH1IDH2TNNI3KEGFR | |
| SCHEMBL16391639 | 0.74 | PTGS2 (0.45) | ALDH1A1TNNI3KEGFR | |
| SCHEMBL20402083 | 0.74 | IDH1 (0.54) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3019480-B1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | disclosed |
| WO-2015006591-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | SMN1; SMN2 3155/4885ALDH1A1 251/4885IDH1 4/4885 |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | IDH2, IDH3B, IDH3A | SMN1; SMN2 3155/4885ALDH1A1 251/4885IDH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.